Global equity and timely access: COVID-19 & beyond 23rd DCVMN Annual General Meeting 2022 report.

The 23rd Annual General Meeting of the Developing Countries Vaccine Manufacturers' Network (DCVMN), co-hosted by Serum Institute of India (SII), gathered over 365 delegates and more than 90 high-level speakers for three days of presentations, discussions, and networking, in Pune, India. The meeting provided a platform for vaccine manufacturers from developing countries to voice their experience, challenges and successes, as they play a critical role in the global research, development and supply of vaccines for achieving vaccine equity through increased collaborations and partnerships. The key topics of the 23rd Annual General Meeting revolved around: the key learnings from COVID-19, pandemic preparedness, vaccine sustainability and scalability, strengthening Africa's local manufacturing, partnerships & collaborations, financing, innovations, and vaccine hesitancy.

Sustainable vaccine manufacturing in low- and middle-Income countries.

The sustainable manufacturing of vaccines in developing countries is critical to increasing equitable access to vaccines and pandemic preparedness globally. Sustainable manufacturing requires that organizations engaged in the development, production and supply of vaccines have viable business models and incentives to manufacture vaccine products. The expanding manufacturing capabilities and capacities of developing countries vaccine manufacturers (DCVMs) are increasingly positioning these organizations to meet the national and regional public health needs in developing countries; however, key industry challenges such as regulatory barriers, low prices and demand uncertainty for vaccine products, and limited R&D funding threaten the long-term viability of vaccine manufacturers.

Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General Meeting.

The Developing Countries Vaccine Manufacturers Network held its 22nd Annual General Meeting in October 2021. Vaccine manufacturing experts, leaders from global public health organizations and dignitaries from governments and multilateral organizations discussed the challenges and opportunities emerging from the COVID-19 pandemic. Over 350 delegates from 33 countries, representing over 70 organizations partook in the meetings deliberations.

Accelerating research and development of new vaccines against tuberculosis: a global roadmap.

To eliminate tuberculosis globally, a new, effective, and affordable vaccine is urgently needed, particularly for use in adults and adolescents in low-income and middle-income countries. We have created a roadmap that lists the actions needed to accelerate tuberculosis vaccine research and development using a participatory process. The vaccine pipeline needs more diverse immunological approaches, antigens, and platforms.

Vaccines, our shared responsibility.

The Developing Countries Vaccine Manufacturers' Network (DCVMN) held its fifteenth annual meeting from October 27-29, 2014, New Delhi, India. The DCVMN, together with the co-organizing institution Panacea Biotec, welcomed over 240 delegates representing high-profile governmental and nongovernmental global health organizations from 36 countries. Over the three-day meeting, attendees exchanged information about their efforts to achieve their shared goal of preventing death and disability from known and emerging infectious diseases.